Adoptive cell therapy of tumor-infiltrating lymphocytes has shown promise for treatment of
refractory melanoma and other solid malignancies; however, challenges to manufacturing
have limited its widespread use. Traditional manufacturing efforts were lengthy,
cumbersome and used open culture systems. We describe changes in testing and
manufacturing that decreased the process cycle time, enhanced the robustness of critical
quality attribute testing and facilitated a functionally closed system. These changes have …